Effectiveness and safety of direct‐acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice

• Published in: Journal of medical virology 2020-12, Vol.92 (12), p.3488-3498
• Main Authors: Margusino‐Framiñán, Luis, Bobadilla‐Pérez, Eva, Cid‐Silva, Purificación, Rodríguez‐Sotelo, Alejandro, Yáñez‐Rubal, Juan C., Mena‐de‐Cea, Álvaro, Suárez‐López, Francisco, Prieto‐Pérez, Andrea, Giménez‐Arufe, Víctor, Delgado‐Blanco, Manuel, Sanclaudio‐Luhia, Ana I., Martín‐Herranz, Isabel, Castro‐Iglesias, Ángeles
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antiviral agents; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; chronic hepatitis C; clinical research; comparative effectiveness research; Comparative studies; Confidence intervals; direct‐acting antivirals; Drug interaction; Drug Interactions; drug safety; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Hepatitis; Hepatitis C; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Humans; Interferon; Male; Medication Adherence; Mental disorders; Mental Disorders - complications; Mental Disorders - drug therapy; Middle Aged; Patients; Prospective Studies; Safety; Sustained Virologic Response; Treatment Outcome; Virology
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.25772

The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug interaction (DDIs) evaluations. Prospective observational comparative study carried out during 3 years. Psychiatric patients were included and mental illness classified by a psychiatric team based on clinical records. Main effectiveness and safety variables were sustained virologic response (SVR) at posttreatment week 12 (SVR12) and rate of on‐treatment serious drug‐related adverse events (AEs), respectively. A total of 242 psychiatric and 900 nonpsychiatric patients were included. SVR12 by intention‐to‐treat (ITT) analysis of psychiatric vs nonpsychiatric patients was 92.6% (95% confidence interval [CI], 89.1‐96.1) vs 96.2% (95% CI, 94.9‐97.5) (P = .02). SVR12 by modified‐ITT analysis was 97.8% (95% CI, 95.0‐99.3) vs 98.4% (95% CI, 97.5‐99.3) (P = .74). 92.2% of psychiatric patients with mental disorders secondary to multiple drug use (MDSDU) and 93.0% of psychiatric patients without MDSDU vs 96.2% of nonpsychiatric patients reached SVR12 (P = .05 and P = .20, respectively). The percentage of adherent patients to DAAs did not show differences between cohorts (P = .08). 30.2% of psychiatric patients and 27.6% of nonpsychiatric patients presented clinically relevant DDIs (P = .47). 1.7% vs 0.8% of psychiatric vs nonpsychiatric patients developed serious AEs (P = .39); no serious psychiatric AEs were present. DAAs have shown a slightly lower effectiveness in psychiatric patients with CHC, as a result of loss of follow up, which justifies the need for integrated and multidisciplinary health care teams. DAAs safety, adherence, and DDIs, however, are similar to that of nonpsychiatric patients.